# Inhibikase Therapeutics Inc. (IKT)

Source: https://www.quantisnow.com/company/IKT
Generated: 2026-11-18T21:19:40.527Z

- Ticker: IKT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2020
- SEC CIK: 0001750149
- Website: inhibikase.com

## About

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

## Latest IKT news and filings

- 2026-11-10 21:38 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inhibikase-therapeutics-inc-6784454)
- 2026-11-10 21:28 UTC [SEC Form 8-K] [Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibikase-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6784302)
- 2026-11-10 21:01 UTC [Earnings] [Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-third-quarter-2026-financial-results-and-highlights-6783724)
- 2026-10-27 12:00 UTC [Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-participation-in-upcoming-investor-conferences-during-november-6758529)
- 2026-10-21 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-inhibikase-therapeutics-inc-6753590)
- 2026-10-21 20:05 UTC [SEC Form 3] [SEC Form 3 filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-inhibikase-therapeutics-inc-6753485)
- 2026-10-20 20:57 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6752390)
- 2026-10-20 20:01 UTC [Leadership Update] [Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors](https://www.quantisnow.com/insight/inhibikase-therapeutics-appoints-scott-wasserman-to-board-of-directors-6752037)
- 2026-10-13 12:50 UTC [Analyst Coverage Initiated] [Chardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price target](https://www.quantisnow.com/insight/chardan-capital-markets-initiated-coverage-on-inhibikase-therapeutics-with-a-6744446)
- 2026-10-02 20:01 UTC [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6734210)
- 2026-09-08 20:41 UTC [SEC Form 8-K] [Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/inhibikase-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6708557)
- 2026-08-26 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6695555)
- 2026-08-14 21:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibikase-therapeutics-inc-6683716)
- 2026-08-14 20:40 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibikase-therapeutics-inc-6683425)
- 2026-08-11 20:27 UTC [SEC Form S-8] [SEC Form S-8 filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-inhibikase-therapeutics-inc-6676093)
- 2026-08-11 20:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inhibikase-therapeutics-inc-6675971)
- 2026-08-11 20:08 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6675781)
- 2026-08-11 20:01 UTC [Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-second-quarter-2026-financial-results-and-highlights-6675574)
- 2026-07-31 20:33 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibikase-therapeutics-inc-6658047)
- 2026-07-31 20:32 UTC [SEC Form 4] [Large owner Ra Capital Management, L.P. disposed of 18,030,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-ra-capital-management-lp-disposed-of-18030000-shares-6658045)
- 2026-07-31 20:05 UTC [SEC Form 4] [Director Berman Dennis N exercised 21,854 shares at a strike of $1.26 (SEC Form 4)](https://www.quantisnow.com/insight/director-berman-dennis-n-exercised-21854-shares-at-a-strike-6657766)
- 2026-07-29 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6653593)
- 2026-07-23 12:32 UTC [SEC Form 8-K] [Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/inhibikase-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6646468)
- 2026-07-23 12:00 UTC [Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-fda-orphan-drug-designation-granted-to-ikt-001-6646287)
- 2026-07-17 21:54 UTC [SEC Form 3] [New insider Ra Capital Management, L.P. claimed ownership of 25,000,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ra-capital-management-lp-claimed-ownership-of-25000000-6641522)
- 2026-07-17 21:52 UTC [SEC Form SCHEDULE 13G filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-inhibikase-therapeutics-inc-6641520)
- 2026-07-14 12:11 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6636138)
- 2026-07-14 12:00 UTC [Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-6636088)
- 2026-07-02 20:01 UTC [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6624963)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Berman Dennis N](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-berman-dennis-n-6620739)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Aurentz Vincent](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-aurentz-vincent-6620736)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Bellini Roberto](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bellini-roberto-6620735)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Munshi Amit](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-munshi-amit-6620734)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Kush Arvind](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kush-arvind-6620733)
- 2026-06-30 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Canner David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-canner-david-6620731)
- 2026-06-29 10:05 UTC [SEC Form 8-K] [Inhibikase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/inhibikase-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6618080)
- 2026-06-10 11:56 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on Inhibikase Therapeutics with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-inhibikase-therapeutics-with-a-new-price-6596393)
- 2026-05-15 20:00 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibikase-therapeutics-inc-6556963)
- 2026-05-12 20:39 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inhibikase-therapeutics-inc-6548592)
- 2026-05-12 20:31 UTC [SEC Form 8-K] [SEC Form 8-K filed by Inhibikase Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-inhibikase-therapeutics-inc-6548498)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IKT
- Earnings history: https://www.quantisnow.com/earnings/IKT
- Dividend history: https://www.quantisnow.com/dividends/IKT
- Insider transactions: https://www.quantisnow.com/insiders/IKT
- Options chain: https://www.quantisnow.com/options/IKT
- SEC 8-K filings only: https://www.quantisnow.com/company/IKT/8-k
- RSS and alerts for IKT: https://www.quantisnow.com/docs/rss-feeds.md
